Literature DB >> 12460559

Apolipoprotein E protects against NMDA excitotoxicity.

Mitsuo Aono1, Yoonki Lee, Elfrida R Grant, Robert A Zivin, Robert D Pearlstein, David S Warner, Ellen R Bennett, Daniel T Laskowitz.   

Abstract

Preclinical and clinical evidence implicates a role for endogenous apolipoprotein E in modifying the response of the brain to focal and global ischemia. To investigate whether apoE modulates the neuronal response to glutamate excitotoxicity, we exposed primary neuronal glial cultures and a neuronal cell line to biologically relevant concentrations of apolipoprotein E prior to NMDA exposure. In both of these paradigms, apolipoprotein E exerted partial protective effects. At neuroprotective concentrations, however, apolipoprotein E failed to block NMDA-induced calcium influx to the same magnitude as the NMDA receptor antagonist MK-801. These results suggest that one mechanism by which apolipoprotein E modifies the central nervous system response to ischemia may be by reducing glutamate-induced excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460559     DOI: 10.1006/nbdi.2002.0541

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  17 in total

Review 1.  Genetic influences on outcome following traumatic brain injury.

Authors:  Barry D Jordan
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

2.  COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia.

Authors:  Elena A Tukhovskaya; Alexey Yu Yukin; Oksana N Khokhlova; Arkady N Murashev; Michael P Vitek
Journal:  J Neurosci Res       Date:  2009-02-15       Impact factor: 4.164

3.  The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage.

Authors:  Daniel T Laskowitz; Beilei Lei; Hana N Dawson; Haichen Wang; Steven T Bellows; Dale J Christensen; Michael P Vitek; Michael L James
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

Review 4.  Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.

Authors:  Li Shan Chiu; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

Review 5.  Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury.

Authors:  Michael L James; Jordan M Komisarow; Haichen Wang; Daniel T Laskowitz
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

6.  An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury.

Authors:  Feng-Qiao Li; Kenneth A Fowler; Jessica E Neil; Carol A Colton; Michael P Vitek
Journal:  J Pharmacol Exp Ther       Date:  2010-04-20       Impact factor: 4.030

7.  Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide.

Authors:  K A Crutcher; H N Lilley; S R Anthony; W Zhou; V Narayanaswami
Journal:  Brain Res       Date:  2009-10-21       Impact factor: 3.252

8.  A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage.

Authors:  Junling Gao; Haichen Wang; Huaxin Sheng; John R Lynch; David S Warner; Lori Durham; Michael P Vitek; Daniel T Laskowitz
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

9.  N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.

Authors:  Zhenyu Sheng; Mary Prorok; Brigid E Brown; Francis J Castellino
Journal:  Neuropharmacology       Date:  2008-05-24       Impact factor: 5.250

10.  Modulating effect of apolipoprotein E polymorphisms on secondary brain insult and outcome after childhood brain trauma.

Authors:  T Y M Lo; P A Jones; I R Chambers; T F Beattie; R Forsyth; A D Mendelow; R A Minns
Journal:  Childs Nerv Syst       Date:  2008-10-07       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.